PI320 Compounds for Local Inflammation Reduction and Lower Systemic Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases such as Inflammatory Bowel Disease (IBD) and other autoimmune diseases are inadequate, leading to substantial healthcare costs and rising prevalence globally, with a need for more effective methods to reduce inflammation locally without systemic side effects.
Innovation Solution
Administration of compounds like PI320 or its pharmaceutically acceptable salts in oral, aerosol, or topical formulations to achieve a higher local concentration, effectively reducing inflammation in gastrointestinal, lung, or skin tissues, regardless of the route of administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory diseases are administered systemically, then inflammation is reduced, but systemic side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds that selectively accumulate in inflamed tissues through enhanced permeability and retention (EPR) effects, allowing the same compound to have different distribution patterns in healthy vs. inflamed tissues. This enables targeted anti-inflammatory action at the disease site while minimizing systemic exposure and side effects.
2Reliability
If higher local concentration of compound is achieved, then inflammation reduction is improved, but the complexity of achieving targeted delivery increases
Solution Approach 1:
The patent employs parameter changes by modifying the physicochemical properties of the compounds (such as lipophilicity, molecular size, and charge) to exploit the altered physiological parameters of inflamed tissues, including increased vascular permeability and enhanced cellular uptake mechanisms. This allows passive targeted accumulation without complex delivery devices.
3Reliability
If new effective treatments are developed for IBD, then patient outcomes improve, but healthcare costs increase due to lifelong treatment needs
Solution Approach 1:
The patent applies partial or excessive action by using compounds that achieve supra-therapeutic concentrations locally in inflamed tissues through passive accumulation mechanisms. This allows the use of lower systemic doses while maintaining effective local concentrations, potentially reducing long-term treatment costs while improving outcomes.
Data Source
AI summary
Methods of reducing inflammation in a subject in need thereof are described, such as a subject having an autoimmune disease, by administering an effective amount of a compound or a pharmaceutically acceptable salt thereof.